Wilprafen - instructions for use, reviews, analogs and forms of release (tablets 500 mg and 1000 mg of solute) for the treatment of ureaplasmosis, chlamydia and other infections in adults, children and pregnancy

In this article, you can read the instructions for using the drug Wilprafen. Comments of visitors of the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Vilprafen in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Wilprafen in the presence of existing structural analogues. Use for the treatment of ureaplasmosis, chlamydia, bronchitis, pneumonia and other infections in adults, children, as well as during pregnancy and lactation.

Wilprafen - antibacterial drug from the group of macrolides. The mechanism of action is associated with a violation of protein synthesis in the microbial cell due to reversible binding to the 50S subunit of the ribosome. In therapeutic concentrations, as a rule, has a bacteriostatic effect, slowing the growth and multiplication of bacteria. When creating high concentrations in the focus of inflammation, a bactericidal effect is possible.

Josamycin (the active substance of the drug Vilprrafen) is active against Gram-positive and Gram-negative bacteria.

As a rule, it is not active against enterobacteria, therefore it negatively affects the microflora of the digestive tract. In some cases, it remains active in the resistance to Erythromycin and other 14- and 15-membered macrolides (streptococci, staphylococci). Resistance to Josamycin is less common than to 14- and 15-membered macrolides.

Pharmacokinetics

After ingestion, Vilprafen is rapidly absorbed from the digestive tract. Eating does not affect bioavailability. Josamycin is well distributed in organs and tissues (with the exception of the brain), creating concentrations exceeding the plasma concentration and remaining at the therapeutic level for a long time.Especially high concentrations of josamycin create in the lungs, tonsils, saliva, sweat and tear fluid. The concentration in the sputum exceeds the concentration in the plasma by 8-9 times. Passes the placental barrier, is secreted into breast milk. It is excreted mainly with bile, excretion in the urine does not exceed 10%.

Indications

Infectious-inflammatory diseases caused by microorganisms sensitive to the preparation:

• upper respiratory tract infection and ENT organs (pharyngitis, tonsillitis, paratonzillitis, laryngitis, otitis media, sinusitis);
• diphtheria (in addition to treatment with diphtheria antitoxin);
• scarlet fever (with hypersensitivity to penicillin);
• infection of the lower respiratory tract (acute bronchitis, exacerbation of chronic bronchitis, community-acquired pneumonia, including caused by atypical pathogens);
• whooping cough;
• psittacosis;
• infection of the oral cavity (gingivitis, pericoronitis, periodontitis, alveolitis, alveolar abscess);
• infection of the eyes (blepharitis, dacryocystitis);
• infections of the skin and soft tissues (folliculitis, furuncle, furunculosis, abscess, acne, lymphangitis, lymphadenitis, phlegmon, panaritium, wounds / incl.postoperative / and burn infections);
• anthrax;
• erysipelas (with hypersensitivity to penicillin);
• urinary tract infection and genital tract (urethritis, cervicitis, epididymitis, prostatitis caused by chlamydia and / or mycoplasmas);
• venereal lymphogranuloma;
• gonorrhea, syphilis (with hypersensitivity to penicillin);
• Gastrointestinal diseases associated with Helicobacter pylori (including gastric ulcer and duodenal ulcer, chronic gastritis).

Forms of release

Tablets 500 mg and 1000 mg (Wilprafen Solutab).

Instructions for use and dosage

The recommended daily dose of the drug for adults and adolescents over the age of 14 years is 1-2 g in 2-3 doses. If necessary, the dose may be increased to 3 g per day.

Children aged 1 year have an average body weight of 10 kg.

The daily dose for children with a body weight of at least 10 kg is prescribed based on a calculation of 40-50 mg / kg body weight daily, divided into 2-3 sessions: children with a body weight of 10-20 kg are prescribed 250-500 mg (1 / 4-1 / 2 tablets dissolved in water) 2 times a day, children with a body weight of 20-40 kg prescribed 500-1000 mg (1 / 2-1 tablets dissolved in water) 2 times a day, children with weight body more than 40 kg - 1000 mg (1 tablet) 2 times a day.

Usually, the duration of treatment is determined by the doctor and is from 5 to 21 days, depending on the nature and severity of the infection. In accordance with the recommendations of the WHO, the duration of treatment of streptococcal tonsillitis should be at least 10 days.

In the schemes of anti-Helicobacter therapy Wilprafen is prescribed in a dose of 1 g 2 times a day for 7-14 days in combination with other drugs in their standard doses:

• famotidine 40 mg per day or ranitidine 150 mg twice daily + josamycin 1 g 2 times a day + metronidazole 500 mg 2 times a day;
• omeprazole 20 mg (or lansoprazole 30 mg, or pantoprazole 40 mg, or esomeprazole 20 mg, or rabeprazole 20 mg) 2 times a day + amoxicillin 1 g 2 times a day + josamycin 1 g 2 times a day;
• omeprazole 20 mg (or lansoprazole 30 mg or pantoprazole 40 mg or esomeprazole 20 mg or rabeprazole 20 mg) twice a day + amoxicillin 1 g 2 times a day + josamycin 1 g 2 times a day + bismuth tricalium dicitrate 240 mg 2 times a day;
• famotidine 40 mg per day + furazolidone 100 mg twice daily + jozamycin 1 g 2 times a day + bismuth tricalium dicitrate 240 mg 2 times a day).

In the presence of atrophy of the gastric mucosa with achlorhydria, confirmed at pH-metry: Amoxicillin 1 g 2 times a day + josamycin 1 g 2 times a day + bismuth tricalium dicitrate 240 mg 2 times a day.

For common and globular acne, it is recommended that Vildrafen be administered at a dose of 500 mg twice daily for the first 2-4 weeks, then 500 mg of josamycin once a day as maintenance treatment for 8 weeks.

Vilprafen Solutab tablets can be taken in various ways: the tablet can be swallowed whole, washed down with water or beforehand, before taking it, dissolved in water. Tablets should be dissolved in at least 20 ml of water. Before the reception, the resulting suspension should be thoroughly mixed.

When taking Wilprafen, it should be borne in mind that if one dose is missed, the dose of the drug should be taken immediately. However, if it's time to take the next dose, you should not take the missed dose, you need to return to the usual treatment regimen. Do not take twice the dose. A break in treatment or premature discontinuation of the drug reduces the likelihood of treatment success.

Side effect

• discomfort in the stomach;
• nausea;
• discomfort in the abdomen;
• vomiting;
• diarrhea, constipation;
• stomatitis;
• decreased appetite;
• pseudomembranous colitis;
• hives;
• angioedema;
• anaphylactoid reaction;
• bullous dermatitis;
• multi-form exudative erythema (including Stephen-Johnson syndrome);
• jaundice;
• dose-dependent transient hearing impairment;
• purpura.

Contraindications

• severe violations of liver function;
• children with body weight less than 10 kg;
• hypersensitivity to the components of the drug;
• increased sensitivity to antibiotics of macrolides.

Application in pregnancy and lactation

It is allowed to use during pregnancy and during breastfeeding after a medical evaluation of the benefit or risk.

The WHO European Office recommends Wilprafen as the drug of choice in the treatment of chlamydial infection in pregnant women.

special instructions

In the case of persistent severe diarrhea, one should keep in mind the possibility of developing a pseudomembranous colitis dangerous for life against the background of josamycin.

In patients with renal insufficiency treatment should be conducted taking into account the results of appropriate laboratory tests (determination of the clearance of endogenous creatinine).

Consideration should be given to the possibility of cross-resistance to various antibiotics from the macrolide group (microorganisms resistant to treatment with antibiotic related chemical structures may also be resistant to josamycin).

Drug Interactions

Because bacteriostatic antibiotics in vitro can reduce the antimicrobial effect of bactericidal antibiotics, their joint use should be avoided. Vilprafen should not be administered together with lincosamides. possibly a mutual reduction in their effectiveness.

Some representatives of the macrolide group slow down the elimination of xanthines (theophylline), which can lead to the appearance of signs of intoxication. Clinical and experimental studies indicate that josamycin has less effect on the elimination of theophylline than other macrolides.

With the joint appointment of Vilprafen and antihistamines containing terfenadine or astemizole, the risk of life-threatening arrhythmias may increase.

There are some reports of increased vasoconstriction after the joint administration of ergot alkaloids and antibiotics from the group of macrolides, incl. Single observation on the background of josamycin.

The joint administration of josamycin and cyclosporine can cause an increase in the level of cyclosporine in the blood plasma and increase the risk of nephrotoxicity.The concentration of cyclosporine in the plasma should be monitored regularly.

With the joint administration of josamycin and digoxin, an increase in the level of the latter in the blood plasma is possible.

Analogues of the drug Vilprafen

Structural analogs for the active substance:

• Wilprafen solute.

Similar medicines:

Other medicines: